Life Sciences
Reunion Neuroscience Reports Earnings, Update on Postpartum Drug Study
Reunion Neuroscience Inc. (NASDAQ: REUN) reported financial results for the third quarter ending December 31, 2022 with no revenue for the biotech company….
Reunion Neuroscience Inc. (NASDAQ: REUN) reported financial results for the third quarter ending December 31, 2022 with no revenue for the biotech company. Reunion did report a net loss from continuing operations of $12.5 million or $1.07 per share for the three versus a loss of $5.9 million or $0.51 per share for the same time period in 2021. As of December 31, 2022, the company held cash, cash equivalents, and investments of $32.4 million.
Postpartum Depression
Reunion said that it continues to advance its serotonergic psychedelic compound called RE104 through the clinic as a potential fast-acting, durable treatment for patients suffering from PPD (postpartum depression). The company said in a statement that one in eight mothers experience PPD, and there remains only one FDA-approved treatment for the condition, which is administered by continuous infusion over a 60-hour inpatient hospital stay and has a black box safety warning due to excessive sedation and potential for sudden loss of consciousness.
As a novel serotonergic psychedelic, single-dose RE104 could potentially provide mothers with fast relief and a quick return to mother-child bonding and breastfeeding (an estimated 24 to 48 hours) due to RE104’s limited-duration psychoactive experience (less than four hours), durable efficacy and rapid washout period. This compares favorably to psilocybin treatments that can last six to eight hours.
In January 2023, Reunion reported that it had completed its Phase 1 interim data analysis, which showed that RE104 was safe and well tolerated, with no serious or severe adverse events. The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving a placebo. RE104 demonstrated robust and pervasive pharmacodynamic effects with a shorter duration of psychedelic experience relative to published data with psilocybin (approximately three to four hours for RE104 versus six to eight hours for psilocybin).
After completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee, Reunion continued with dose escalation to seek additional safety, pharmacokinetic and pharmacodynamic data. Exploring further doses with the two additional planned cohorts will provide Reunion with valuable data to inform the selection of a recommended Phase 2 dose.
Reunion also reported that it has submitted the Phase 1 data to an upcoming 2023 medical congress and to the FDA in preparation for initiating a randomized Phase 2 study evaluating RE104 versus placebo in the treatment of women with PPD in the second half of 2023. It is expected that the multicenter trial will enroll approximately 40 patients from 20 centers across North America.
Mr. Mayes added, “We also welcomed Dr. Robert Alexander as Chief Medical Officer, an accomplished pharmaceutical executive who brings to Reunion a proven track record in psychopharmacology. We remain on track to share the results of our Phase 1 study with the FDA in preparation for Phase 2 development in postpartum depression (PPD) later this year.” Alexander was a former executive at Takeda, Pfizer, AstraZeneca, GSK, and Merck, with extensive experience in psychopharmacology, having conducted or supervised clinical studies in a broad range of neurologic and psychiatric indications.
The post Reunion Neuroscience Reports Earnings, Update on Postpartum Drug Study appeared first on Green Market Report.
pharmacodynamic
medical
biotech
psilocybin
psychedelic
psychoactive
depression
fda
nasdaq
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….